Compare Marsh & McLennan Companies, Inc. (MRSH) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Tilray Brands Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 158.9× Tilray Brands Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Tilray Brands Inc for 31 Days on average.
| MRSH | TLRY | |
|---|---|---|
Market Cap | $84.31B | $530.54M |
Volume | 3,948,947 | 9,099,075 |
Sector | Financials | Health |
52-Week High | $207.02 | $21.00 |
52-Week Low | $157.32 | $3.57 |
Typical Hold Time | 109 Days | 31 Days |
Enterprise Value | $104.99B | $684.46M |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $176.67, up 1.73% today, near its consensus price target of $202.71. The stock shows a bullish technical trend with support at $174 and resistance at $178. Recent earnings beats and the acquisition of Accel Holdings highlight strong operational momentum. Revenue grew to $27.0B in 2025, with a net income margin of 14.24% and a P/E ratio of 21.57, indicating solid profitability amid moderate valuation.
The outlook remains positive with consistent earnings outperformance and strategic acquisitions driving growth. Risks include elevated debt levels and potential margin pressure. Analysts are mostly neutral (65% Hold), but the stock offers upside to the price target. Investors should weigh strong cash flow generation against macroeconomic sensitivities in the insurance sector.
TLRY trades at $3.54, down 4.71% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows negative technical momentum with consecutive earnings misses and widening losses despite revenue growth. Recent financials reveal a net loss of $2.19B for 2025, though analyst consensus maintains a $65.01 price target with 25% buy ratings. Business developments include new product launches and leadership changes under Tilray's expanded beverage portfolio.
Outlook remains challenged by profitability concerns and high debt, but potential cannabis regulatory shifts could catalyze recovery. Investment opportunity hinges on execution improvement and market expansion, while risks include sustained cash burn and competitive pressures in the cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
